March 07, 2023
A pharmaceutical industry proposal to subsidize the use of taxpayer-funded drugs "clearly involves quid pro quo exchanges" that the industry itself says are legally problematic, federal health care officials said Tuesday, rebutting a sweeping challenge to kickback enforcement.
January 09, 2023
The U.S. Supreme Court refused Monday to entertain Pfizer's high-profile challenge to a powerful kickback law that has generated billions of dollars in fraud settlements, but the underlying controversy continues in nearly identical litigation that might soon open a circuit split.
January 05, 2023
The never-not-busy False Claims Act realm will be extra active in 2023 as the U.S. Supreme Court delivers at least one FCA opinion — and perhaps two or even three — in headliner cases during a year in which attorneys are also eyeing a new circuit split and emerging enforcement frontiers.
November 09, 2022
A charity bankrolled by drugmaker dollars sued a federal health-fraud watchdog on Wednesday over the specter of kickback enforcement targeting financial help for lucrative medications, echoing a prominent challenge Pfizer has taken to the U.S. Supreme Court.